MedTrace Logo

Study of Biomarker Profiles in Asia Pacific erb2+/HER2 Breast Cancer Patients Treated With Lapatinib

NCT01248897 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 158

Last updated 2018-06-19

No results posted yet for this study

Summary

The purpose of this study is to understand how information of 3 specific biomarkers can provide guidance to physicians in the treatment of erbB2 positive breast cancer patients.

Conditions

  • Neoplasms, Metastasis

Interventions

OTHER

This study is non-interventional study, so this section is not applicable.

This study is non-interventional study, so this section is not applicable.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-17
Primary Completion
2013-12-01
Completion
2014-09-05

Countries

  • Hong Kong
  • Philippines
  • Singapore
  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01248897 on ClinicalTrials.gov